June 24, 2026   |   Read online The Pump the Other 70% Have Been Waiting For — (MODD) Is Today’s Top Idea Any content you receive is for information purposes only. Always conduct your own research. *Sponsored New Coverage Alert: A San Diego Device Maker Just Cleared the FDA's Bar and Is Heading Into Its First Commercial Launch A Fresh FDA Clearance and a First-of-Its-Kind Tubeless Patch Pump Put Modular Medical, Inc. (NASDAQ: MODD) on Daily Edge Report's Watchlist for Wednesday, June 24, 2026 Don't Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Look Into (MODD) Right Now… June 24, 2026 The Pump the Other 70% Have Been Waiting For — (MODD) Is Today’s Top Idea Dear Reader, Roughly 8.4 Americans rely on insulin to manage their diabetes — and 6M have to take it every day. Yet only about 20% of them use an insulin pump. The vast majority stay on daily injections, often because traditional pumps are seen as too complex, too cumbersome, or too expensive. A small San Diego company believes it has built the device that finally reaches that overlooked segment — and it just got the regulatory green light to sell it. That company is Modular Medical, Inc. (NASDAQ: MODD). On April 9, 2026, the company announced FDA 510(k) clearance for its next-generation Pivot tubeless insulin patch pump — the event that turns a development-stage story into a company with a clear path to its first commercial sales. Management has described the clearance as a major de-risking moment, and it sets up a launch sequence that begins with initial patients in June 2026 and builds toward a full commercial launch in the fall of 2026. The share structure is worth understanding up front, because it changed dramatically this spring. On March 31, 2026, (MODD) On March 31, 2026, (MODD) reduced its outstanding shares from roughly 139.8M to about 4.66M. The current float is around ~2.22M shares. This remains a small-cap with a market capitalization near $23.48M. Recent history tells you how much this name can move. (MODD)’s 52-week range, adjusted for the share restructuring, spans from roughly $3.13 to $30.00 — a reminder that small device names can swing hard in both directions. We'd note plainly that the ticker sits closer to the low end of that band today, with shares recently under $5. A lineup of potential catalysts have earned (MODD) a place at the top of our watchlist for tomorrow, June 24, 2026. Modular Medical, Inc. is a San Diego–based, development-stage medical device company focused on the design, development, and commercialization of insulin pumps. Its mission, in the company's own framing, is "diabetes care for the rest of us" — bringing pump therapy to the large population of insulin users who have stayed on injections. The company's pedigree is part of the story. (MODD) was founded by Paul DiPerna, a microfluidics engineer who previously founded Tandem Diabetes Care in 2005 and invented its t:slim insulin pump — a product that went on to anchor a company that surpassed $9B in market capitalization in 2021. That track record of taking an insulin-pump concept from the bench to commercial scale is a meaningful part of why this much smaller company draws attention. The flagship product is Pivot, described as the first two-part tubeless patch pump featuring a removable 3 mL reservoir, a disposable battery, smartphone connectivity for dosing and monitoring, and electronic dosing accuracy — all without tubing or the need to recharge. The removable two-part design is the core differentiator: users can detach the pump for showering, sports, or discretion, and the architecture is built for low-cost, scalable manufacturing. An earlier product, MODD1, secured FDA clearance previously and served as the technical foundation; the company has since converted its manufacturing line toward Pivot production. The revenue model is straightforward in concept — sell the reusable pump and recurring disposable components — but it is entirely forward-looking. (MODD) is pre-revenue today, with commercial sales only now beginning to ramp. Initial production capacity is set to support roughly 6,000 users, with the platform designed for rapid scaling as demand develops. About (MODD)’s Market Sector (MODD) sits inside the insulin-delivery segment of medical devices, a market defined by a stark adoption gap. The broader U.S. insulin pump market has been estimated at roughly $8B. The specific niche Pivot targets — the "almost-pumpers," adults who could benefit from a pump but remain on injections — is framed by the company as a roughly $3B addressable market. The analytical case rests on that adoption gap. Around 70% of insulin-dependent adults remain on multiple daily injections, and the company attributes that to what it calls the "3 Cs": complexity, cumbersomeness, and cost. Incumbent pump makers — Insulet's Omnipod, Tandem, Medtronic — have built large franchises largely among "superusers" and the more intensively managed Type 1 population. The strategic thesis behind Pivot is that a simpler, removable, lower-cost device can convert a slice of the underserved majority that incumbents have struggled to reach. Modular’s first-mover claim on a "removable two-part" form factor is a genuine differentiator and its introduction into the $3B market creates significant growth potential for the company.  Why (MODD) Caught Our Attention The recent news flow has been dense and, for a development-stage name, unusually eventful. FDA clearance opens the door.  The April 9 510(k) clearance for Pivot is a major milestone for (MODD). It permits commercial sale and distribution in the U.S. and converts the company's narrative from "awaiting regulatory review" to "preparing to sell." The Pivot launch sequence.  On June 4, 2026, (MODD) launched PivotPump.com, a patient-facing website, and reaffirmed that initial patients were expected to begin on the system in June, with a full commercial launch targeted for the fall of 2026. Software enhancements — variable bolus, improved alarms, and eventual ACE/AID compatibility — are in development, and a CE Mark for European access is targeted for around Q4 2026 to Q1 2027. 6 Reasons (MODD) Is At The Top Of Our Watchlist — Wednesday, June 24, 2026 1. FDA Cleared: The single most important development is regulatory — (MODD) secured FDA 510(k) clearance for its Pivot tubeless patch pump in April 2026, clearing the path to commercial sale. 2. Differentiated Design: What sets (MODD) apart is a first-of-its-kind two-part removable tubeless patch pump with a detachable reservoir and disposable battery, aimed squarely at users who've avoided traditional pumps. 3. Launch Window: With initial patients expected in June and a full rollout targeted for the fall, (MODD) is entering what may be the most closely watched stretch of its history right now. 4. Founder Pedigree: The person behind (MODD) is Paul DiPerna, the engineer who founded Tandem Diabetes and invented the t:slim pump — a rare track record of taking an insulin pump from concept to commercial scale. 5. Large Underserved Market: Roughly 70% of insulin-dependent adults remain on injections, and (MODD) is targeting that gap within an insulin-pump market estimated near $8B. 6. Low Float: With a float of ~2.22M shares, shifts in demand can produce outsize moves. Check Out (MODD) Right Away What we're watching with Modular Medical is a company arriving at the exact moment its entire story has been building toward: a cleared product, a launch calendar, and a founder who has walked this path before. The technology is differentiated, the target market is genuinely large and underserved, and the regulatory risk that hangs over most device markers has, for the lead product, now been cleared. We'll be candid that this is a higher-risk name. It is pre-revenue, it has leaned heavily on dilutive financing, its cash runway warrants close attention, and it is stepping into a ring with much larger competitors. A cleared device is not the same as a commercial success, and the months ahead — first patients, early reorder rates, and how the company funds its ramp — will tell the real story. But that combination — a fresh FDA clearance, a credible founder, a differentiated design, and a launch that starts now — is exactly the kind of developing narrative this report exists to flag early. We'll have all eyes on (MODD) this morning, Wednesday, June 24. We encourage you to check it out now. Sincerely, Joel Locke Senior Editor The Daily Edge Report DailyEdgeReport.com (“DailyEdgeReport” or “DER” ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 06/23/2026 and ending on 06/24/2026 to publicly disseminate information about (MODD:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC fifteen thousand USD (“Funds”). These Funds were part of the ninety thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (MODD:US). Please see important disclosure information here: https://dailyedgereport.com/disclosure/modd-bUGa1/#details   Update your email preferences or unsubscribe here © 2026 Daily Edge Report 1401 Pennsylvania Ave Suite 105 Wilmington, Delaware 19806, United States Terms of Service